VEGF-A165b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney by Stevens, Megan et al.
Stevens, Megan and Neal, Christopher R. and Salmon, 
Andrew H.J. and Bates, David O. and Harper, Steve J. 
and Oltean, Sebastian (2017) VEGF-A165b protects 
against proteinuria in a mouse model with progressive 
depletion of all endogenous VEGF-A splice isoforms 
from the kidney. Journal of Physiology, 595 (19). pp. 
6281-6298. ISSN 1469-7793 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/43073/8/Stevens_et_al-2017-The_Journal_of_Physiology.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
J Physiol 000.00 (2017) pp 1–18 1
Th
e
Jo
u
rn
al
o
f
Ph
ys
io
lo
g
y
VEGF-A165b protects against proteinuria in a mouse model
with progressive depletion of all endogenous VEGF-A
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Key points
 Progressive depletion of all vascular endothelial growth factor A (VEGF-A) splice isoforms
from the kidney results in proteinuria and increased glomerular water permeability, which are
both rescued by over-expression of VEGF-A165b only.
 VEGF-A165b rescues the increase in glomerular basement membrane and podocyte slit width,
as well as the decrease in sub-podocyte space coverage, produced by VEGF-A depletion.
 VEGF-A165b restores the expressionof platelet endothelial cell adhesionmolecule in glomerular
endothelial cells and glomerular capillary circumference.
 VEGF-A165b has opposite effects to VEGF-A165 on the expression of genes involved in end-
othelial cell migration and proliferation.
Abstract Chronic kidney disease is strongly associated with a decrease in the expression of
vascular endothelial growth factor A (VEGF-A). However, little is known about the contribution
of VEGF-A splice isoforms to kidney physiology and pathology. Previous studies suggest that the
splice isoformVEGF-A165b (resulting fromalternative usage of a 3′ splice site in the terminal exon)
is protective for kidney function. In the present study, we show, in a quad-transgenic model, that
over-expression of VEGF-A165b alone is sufficient to rescue the increase in proteinuria, as well as
glomerular water permeability, in the context of progressive depletion of all VEGF-A isoforms
from the podocytes. Ultrastructural studies show that the glomerular basement membrane is
thickened, podocyte slit width is increased and sub-podocyte space coverage is reduced when
VEGF-A is depleted, all ofwhich are rescued inVEGF-A165b over-expressors. VEGF-A165b restores
the expression of platelet endothelial cell adhesionmolecule-1 in glomerular endothelial cells and
glomerular capillary circumference. Mechanistically, it increases VEGF receptor 2 expression
both in vivo and in vitro and down-regulates genes involved in migration and proliferation of
endothelial cells, otherwise up-regulated by the canonical isoform VEGF-A165. The results of the
present study indicate that manipulation of VEGF-A splice isoforms could be a novel therapeutic
avenue in chronic glomerular disease.
(Resubmitted 11 April 2017; accepted after revision 17 May 2017; first published online 2 June 2017)
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Abbreviations ACTG1, actin gamma-1; ciGEnCs, conditionally immortalized glomerular endothelial cells; CKD,
chronic kidney disease;DEPC, diethylpyrocarbonate;GBM, glomerular basementmembrane;GFR, glomerular filtration
rate; GSI, glomerulosclerosis index; ISH, in situ hybridization; KD, knockdown; KO, knockout; LpA/Vi, glomerular
ultrafiltration coefficient normalized to glomerular area; PAS, periodic acid-Schiff; PECAM, platelet endothelial cell
adhesion molecule; PFA, paraformaldehyde; SHC1, Src homology 2 domain containing transforming protein 1; SPS,
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sub-podocyte space; SSC, saline sodium citrate; TBS, Tris-buffered saline; uACR, urinary albumin creatinine ratio;
VEGF-A, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor; WT, wild-type.
Introduction
Chronic kidney disease (CKD) is a major health problem
worldwide. In the USA, it is estimated that 13% of the
general populationhasCKDstages 1–4 (Snyder et al. 2009)
and, in Europe, the prevalence is higher at 16% (Meguid El
Nahas & Bello, 2005). The renal replacement population
inevitably consumes a disproportionate amount of health
resources and is associated with a poor prognosis, with a
5 year survival rate of close to 50% for dialysis patients
(https://www.renalreg.org/data/). In large part, this is
contributed to by the association of proteinuria and CKD
with increased risk of cardiovascular disease andmortality
(Go et al. 2004; Allison, 2010; Matsushita et al. 2010).
Therefore, it is critical to elucidatemolecular determinants
of glomerular dysfunction and CKD and find new ways to
manipulate them for therapeutic benefit.
Abnormal expression of vascular endothelial growth
factor A (VEGF-A) in the kidney has been
reported in many renal pathologies, such as diabetic
nephropathy, several glomerulopathies (e.g. membranous
glomerulopathy, focal-segmental glomerulosclerosis) and
acute and chronic transplant rejection (Schrijvers
et al. 2004). Interestingly, a recent study that
analysed expression networks in 157 biopsies of
patients with CKD resulting from various causes
identified VEGF-A as one of the genes significantly
correlated with renal function, both in glomerular
and tubulointerstitial compartments (Martini et al.
2014). Moreover, with the advent of anti-VEGF/VEGF
receptor (VEGFR)2 therapies in oncology, several side
effects including renal complications have been reported,
with proteinuria resulting from thrombotic micro-
angiopathy, minimal change nephrotic syndrome and
focal-segmental glomerulosclerosis (Chen & Cleck, 2009;
Ollero & Sahali, 2014). Therefore, there is a clear
physiological role of VEGF-A in the kidney, which
is affected in various pathologies. This suggests that
restoring the function of VEGF-A could be therapeutically
useful.
Several studies have reported that knockout (KO)
or knockdown (KD) of VEGF-A from the kidney in
transgenic mouse models has various deleterious effects
depending on the age at which the KO/KD is induced
or whether they are challenged on a diabetic background
(Eremina et al. 2008; Sivaskandarajah et al. 2012; Veron
et al. 2012). However, these studies have not until now
taken into account the effect of VEGF-A splice isoforms,
such as VEGF-A165b, resulting from an alternative 3′ splice
site in the terminal exon. VEGF-A165b has been shown
to be a partial agonist/antagonist of VEGFR2 and to be
protective of kidney function (Bates et al. 2002; Bevan et al.
2008; Harper & Bates, 2008; Qiu et al. 2010; Oltean et al.
2012;Oltean et al.2015) in vivoandprotective forpodocyte
function in vitro (Bevan et al. 2008); however, it does
not affect normal kidney function when over-expressed
in a podocyte-specific manner (Qiu et al. 2010) and
it is able to counteract the pro-permeability function
of the VEGF-A165 splice isoform in vivo (Oltean et al.
2012).
Given the pathologies associated with VEGF-A
inhibition and the strong association of decreased
glomerular filtration rate (GFR) with low VEGF-A
expression, we have addressed the hypothesis that a
simplified injury model of progressive cell-specific
inducible depletion of VEGF-A from the kidney can be
rescued by over-expressing only the VEGF-A165b isoform.
This the first study to determine the effects of podocyte
VEGF-A165b over-expression when all other isoforms
of VEGF-A are depleted. We find that a KD of podocyte
VEGF-A expression in adult mice results in micro-
albuminuria and increased glomerular permeability,
without any evidence of glomerulosclerosis/fibrosis.
Furthermore, we find that VEGF-A165b alone is sufficient
to restore normal kidney function, and we go on to
describe its mechanism of action in vivo and how
this differs from that of VEGF-A165a in conditionally
immortalized glomerular endothelial cells (ciGEnCs) in
culture.
Methods
Ethical approval
All experiments were conducted in accordance with UK
legislation and local ethical committee approval, as well
as in accordance with the principles and regulations
as described by Grundy (2015). Animal studies were
approved by University of Bristol research ethics
committee.
Materials
Allmaterialswere obtained fromSigma (Poole,UK)unless
otherwise stated.
Mouse models
Transgenic mice were obtained from in-house
colonies. Mice were entered into studies at 8 weeks
of age and wild-type (WT) littermate controls were
used for comparison. Details for the pod-rtTA and
Neph-VEGF-A165b mice are provided elsewhere (Qiu
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et al. 2010; Oltean et al. 2012). Offspring were genotyped
by PCR analysis of an ear notch for each of the four
transgenes: Pod-rtTA, Tet-O-Cre, LoxP VEGF-A and
Neph-VEGF-A165b. Excision of exon 3 of VEGF-A
in the podocytes was induced by adding doxycycline
(5 mg ml−1) to light-protected drinking water containing
5% w/v sucrose. Doxycyline was administered for up to
14 weeks to inducible podocyte-specific VEGF-A-KO
mice, VEGF-A-KO mice × Neph-VEGF-A165b mice and
WT littermate controls (+:+:Pod-rtTA:LoxP-VEGF).
VEGF-A165b over-expression was constitutive in
podocytes in mice containing the Neph-VEGF-A165b
transgene. Four to 12 mice were used per group
over two experiments. Mice were culled at the end
of the experiment via Schedule 1 killing (cervical
dislocation).
In situ hybridization (ISH)
ISH was carried out on 5 μM thick, 4%
paraformaldehyde-fixed kidney cortex sections using
a digoxigenin-labelled VEGF-A164 riboprobe on
VEGF-A-KO and WT littermate controls 4, 10 and
14 weeks after induction with doxycycline. ISH for
VEGF-A164 mRNA was used to determine the level of
VEGF-A KD in the glomerulus. The VEGF-A164 cDNA
cloned into a Bluescript II ks plasmid was a kind gift from
Vera Eremina (University of Toronto, Toronto, Canada).
Digoxigen-labelled probes were prepared in accordance
with the manufacturer’s instructions (Roche, Mannheim,
Germany). Sections were air-dried overnight at room
temperature and then treated with 15 μg ml−1 proteinase
K (Roche) in diethylpyrocarbonate (DEPC)-treated PBS
at 37°C for 5 min.
Sections were fixed in 4% paraformaldehyde (PFA) in
DEPC-treated PBS at room temperature for 7 min, and
then washed firstly in DEPC-treated PBS and then in
2 × saline sodium citrate (SSC) buffer. Sections were
pre-hybridized in preheated (60°C) hybridization buffer
(50% formamide, 5 × SSC, 0.5% Chaps; 0.1% Triton
X-100, 5 μg ml−1 yeast tRNA; 5 μg ml−1 heparin, 5 mM
EDTA, 2%blockingpowder) in a 50% formamide/5×SSC
humidified chamber at 60°Cfor 1h.Thepre-hybridization
bufferwas removed and replacedwithhybridizationbuffer
containing the probe at 1 μg ml−1 and incubated over-
night at 60°C. The next day, slides were washed in a
50% formamide/0.2 × SSC solution at 60°C for 15 min.
Sections were then incubated in NT blocking buffer
(Roche) for 30 min before incubating in primary anti-
body: sheep anti-digoxigenin AP Fab fragments (Roche)
diluted 1:2000 in NT blocking buffer. Primary antibody
was left on for 2 h at room temperature. Slides were
washed in Tris-buffered saline (TBS)-Tween (0.1%) with
2 mM levamisole for 30 min and then in APB buffer
(1 × TBS-Tween (0.1%) with 0.2 M levamisole) with
agitation for 15min. Slides were then coated in BMpurple
colour substrate (Roche) and placed in a dark humid
chamber at room temperature overnight or until colour
developed. Fotr to eight mice were used from each group,
with fiuve to seven glomeruli analysed permouse. Staining
was repeated three times per mouse and averages were
taken.
RT-PCR
RNA was extracted with Trizol (Invitrogen,
Carlsbad, CA, USA) from WT, VEGF-A-KO and
VEGF-A-KO × Neph-VEGF-A165b kidney cortex and
then DNaseI (Promega, Madison, WI, USA) digested
to prevent genomic DNA contamination. Next, 2 μg of
DNase-treated RNA was reverse transcribed into cDNA
with avian myeloblastosis virus reverse transcriptase
in accordance with the manufacturer’s instructions
(Promega). Both cDNA and RNA [(RT−) control] were
subjected to PCR as described previously (Qiu et al. 2010)
to indicate VEGF-A165b transgene expression with a band
at 199 bp. Three mice per group were studied and the
experiment was repeated three times.
Functional phenotype
Urine was collected by housing mice in metabolic cages
for 6–12 h. Urine was first collected before doxycycline
administration began for baseline readings, and then
every 2 weeks up until mice were killed 14 weeks after
induction began. The urinary albumin creatinine ratio
was used as a measure of urinary protein loss. Albumin
was quantified with an albumin enzyme-linked immuno-
sorbent assay (Bethyl Laboratories, Inc., Montgomery,
TX, USA) and creatinine was quantified using an
enzymatic spectrophotometric assay (Konelab T-Sereis
981845; Thermo Fisher Scientific, Waltham, MA, USA).
Four to 12 mice were used from each group, with assays
being repeated in triplicate. Upon culling mice, blood
was collected for plasma creatinine analysis. Kidneys were
immediately removed and a small, finely diced, section of
cortexwas fixed in 2.5%gluteraldehyde in 0.1M cacodylate
buffer for electron microscopy. Sections of kidney cortex
were snap frozen in liquid nitrogen and stored at −80°C
for subsequent RNA and protein analysis, and also in
embedding medium for sectioning and staining. The
remaining kidney was used to harvest glomeruli using
a standard sieving technique for glomerular ultrafiltration
coefficient normalized to glomerular area (LpA/Vi)
experiments using an oncometric assay described pre-
viously (Salmon et al. 2006). In one set of experiments,
glomeruli from WT and Neph-VEGF-A165b mice were
incubated for 1 h with 100 nM PTK787 at 4°C before
measuring glomerular LpA/Vi. Four to nine mice were
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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used from each group, with four to five glomeruli being
analysed per mouse.
Structural and ultrastructural phenotype
Regarding structural and ultrastructural phenotype,
4% paraformaldehyde-fixed kidney cortex sections were
stained with a periodic acid-Schiff (PAS) and Masson’s
trichrome blue stain to determine the structural
glomerular phenotype. PAS stained glomeruliwere blindly
scored using the widely-used glomerulosclerosis index
(GSI) (1 = normal; 2 = 25% sclerosis; 3 = 50% sclerosis;
4= < 75% sclerosis).Masson’s trichrome stained sections
were blindly assessed for percentage area of glomeruli
stained blue (collagen).
The ultrastructural phenotype was determined using
2.5% glutaraldehyde-fixed diced kidney cortex, which
was postfixed in 1% osmium tetroxide and embedded
in Araldite (Agar Scientific, Stansted, UK). Sections of
50–100 nm thickness were stained with 3% (aqueous)
uranyl acetate and Reynolds’ lead citrate solution. From
the images taken, detailedmeasurementsof the glomerular
filtration barrier were taken by a blinded experimenter
at random points using Photoshop (Adobe Systems Inc.,
San Jose, CA, USA). These included glomerular basement
membrane (GBM) thickness, endothelial fenestration
number, average podocyte foot process width, average
podocyte slit width and percentage sub-podocyte space
(SPS) coverage. Three mice were used per group.
Immunofluorescence
Kidney samples for immunofluorescence studies were
snap frozen in OCT embedding medium (Invitrogen).
Then, 5 μm sections were mounted on to glass slides
and fixed for 15 min with 4% PFA. Primary anti-
bodies used were anti-VEGFR2 (dilution 1:50; Cell
Signaling Technology, Beverly, MA, USA), anti-nephrin
(dilution 1:250; Acris GmbH, Herford, Germany),
anti-podocin (dilution 1:1:500; Sigma, St Louis, MO,
USA) and anti-platelet-endothelial cell adhesionmolecule
(PECAM)-1 (dilution 1:1:500; BD Biosciences, San Jose,
CA, USA). The appropriate Alexa-Fluor secondary anti-
body was used and sections were imaged on a fluorescence
microscope. Staining was normalized to glomerular area
to calculate the percentage glomerular area covered by
staining. Z stack confocal imaging was used to access
co-localization. Three mice were assessed per group, over
three experiments. A minimum of 36 glomeruli were
analysed per mouse.
Cell culture studies
ciGEnCs (Satchell et al. 2006) were differentiated at 80%
confluence with EBM2 media (Lonza Inc., Allendale, NJ,
USA). Prior to treatment, cells were serum starved for
6 h before the addition of vehicle (PBS) 1 nM VEGF-A165,
1 nM VEGF-A165b, or a combination of both. Treatments
lasted for 0.25, 0.5, 1, 2, 24 and 48 h. Protein was then
extracted using aNP40 lysis buffer and RNAwas extracted
using Trizol (both from Invitrogen). Treatments were
always carried out in triplicate with the relative controls.
Experiments were repeated three times.
Western blotting
Western blotting was performed on protein extracted
from sieved glomeruli or kidney cortex and on protein
extracted from treated ciGEnCs. Samples were run
on mini-PROTEAN R© TGX Stain FreeTM pre-cast gels
(4–15%; Bio-Rad, Hercules, CA, USA) and transferred
onto polyvinylidene fluoride membranes. Membranes
were blocked in 3% BSA in TBS-Tween (0.1%) for
1 h at room temperature and probed using anti-P-Tyr
(dilution 1:1000; 9411; Cell Signaling) (after immuno-
precipitation forVEGFR2; 55B11;Cell Signaling), nephrin
(dilution 1:1000; Acris GmbH), podocin (dilution
1:1000; Sigma), PECAM (dilution 1:1000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), p-Akt (dilution
1:1000; Cell Signaling), Akt (dilution 1:1000; Cell
Signaling), p-p42/44 MAPK/p-ERK1/2 (dilution 1:1000;
Cell Signaling), p-42/44 MAPK/ERK1/2 (dilution 1:1000;
Cell Signaling), VEGF-A165b (dilution 1:500; R&D
Systems, Minneapolis, MN, USA), VEGF-A164 (dilution
1:1000; Abcam, Cambriudge, UK), actin gamma-1
(ACTG1) (dilution 1:1000; Genetex, Irvine, CA, USA) or
Srchomology2domain containing transformingprotein1
(SHC1) (dilution 1:1000; R&D Systems) at 4°C overnight.
The appropriate Licor fluorescent secondary antibodies
were applied for 2 h at room temperature andmembranes
were imaged using a Licor Imaging System (Licor, Lincoln,
NE,USA). Total proteinwasmeasured using aGel-Doc EZ
(Bio-Rad), allowing quantification of total protein from
the membrane. Experiments were repeated three times
with the relative controls on the same blot.
PCR array and validation
RNA extracted from 1 h treated ciGEnCs was used to
make cDNA using the RT-PCR process described above.
A human VEGF-A pathway TaqMan fast array (Applied
Biosciences, Foster City, CA, USA) was used to examine
gene expression profiles from the cDNA. Forty-six
candidate genes were tested, plus two housekeeping
control genes. The fold change in gene expression relative
to control (Ct) was measured in cDNA from ciGEnCs
treated for 1 h with either VEGF-A165 or VEGF-A165b.
cDNA was then subjected to quantitative RT-PCR using
gene specific primers for candidate genes identified within
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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thePCRarray for validation.Cellswere treated in triplicate
over four experiments.
Statistical analysis
To test our hypothesis that the podocyte-specific
over-expression VEGF-A165b plays a protective role in
the inducible podocyte-specific VEGF-A KD model of
glomerular disease, we performed statistical analysis using
Prism (GraphPad Software Inc., San Diego, CA, USA).
The appropriate statistical test for the data set was used
the analyse the data, including Student’s unpaired t test
and one-way ANOVA, incorporating the non-parametric
equivalents if the data did not fall under the normal
distribution. All analysis was blinded by the researcher,
restricting bias. Details of numbers of repeats can be
found under each individual method. The researcher
was kept blinded to the group during imaging and
analysis.
Results
Albuminuria resulting from progressive depletion of
VEGF-A in kidneys of inducible transgenic KO mice is
rescued by constitutive expression of the human
VEGF-A165b splice isoform
We investigated whether the VEGF-A165b isoform is
sufficient as a lone isoform for normal kidney function
in vivo. Accordingly, we took advantage of a transgenic
mousemodelwithover-expressionof humanVEGF-A165b
under a nephrin promoter that we had characterized pre-
viously (Qiu et al. 2010), which has podocyte-specific
constitutive over-expression of VEGF-A165b in the
glomerulus. This was crossed with a podocyte-specific
and inducibleVEGF-A-KOtoobtainquadruple transgenic
mice (VEGF-A-KO × Neph-VEGF-A165b) (Fig. 1A).
Induction of VEGF-A-KO from the kidney was started
by adding doxycycline to the drinking water. At 4 weeks
post-induction, there was no difference in amount
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Figure 1. Generation of inducible
podocyte-specific VEGF-A-KO mice that
over-express VEGF-A165b in the podocytes
A, the inducible podocyte-specific VEGF-A-KO
mouse was generated from three starter colonies:
Pod-rtTA, Tet-O-Cre and LoxP VEGF-A (LoxP sites
flanking exon 3). In the absence of doxycycline
(yellow circles), reverse tetracycline trans-activator
protein (rtTA, red crescents), under the control of
the podocin promoter, is unable to bind to the
Tet-O-Cre transgene at the tetracycline responsive
element. When doxycycline is added to the
drinking water, rtTA is able to bind and initiate
transcription of Cre recombinase in podocytes,
resulting in excision of exon 3 from VEGF-A, and
thus preventing the expression of protein VEGF-A
in the podocytes. This was crossed with the
Neph-VEGF-A165b mouse to obtain the quadruple
transgenic. B, mouse VEGF-A164 mRNA levels were
quantified by ISH on sections from the renal cortex.
VEGF-A164 mRNA expression was calculated (C) by
normalizing the area stained purple (highlighted in
green) to the total glomerular area, and expressing
VEGF-A164 expression as a percentage of
glomerular area relative to the mean WT control
group for each time point (n = 4–8 mice, 21–56
glomeruli. ∗∗P < 0.01; unpaired Student’s t test for
VEGF-A-KO vs. WT littermate controls for the same
time point). [Colour figure can be viewed at
wileyonlinelibrary.com]
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of VEGF-A in the glomeruli of VEGF-A-KO mice
compared to WT (+:+:pod-rtTA:VEGF-LoxP) controls,
as quantified by in situ hybridization; however, significant
and progressive depletion of VEGF-A from the kidney
was observed at 10 and 14 weeks post-induction (Fig. 1B
and C) in the Pod-rtTA:TetO-Cre:VEGF-LoxP triple
transgenic mice. KD of VEGF-A164 protein was also
observed in the sieved glomeruli from VEGF-A-KO
and VEGF-A-KO × Neph-VEGF-A165b mice via western
blotting. VEGF-A165b over-expression was confirmed by
RT-PCR and western blotting and showed an average
three-fold increase in VEGF-A165b expression in the
kidney cortex of the quadruple transgenic mice, as
described previously byQiu et al. (2010) (data not shown).
The urinary albumin:creatinine ratio (uACR) was
significantly increased in VEGF-A-KO mice compared
to WT littermates at 10 and 14 weeks post-induction
(WT; 93.9 ± 14.7, 143.8 ± 31.3, VEGF-A-KO;
330.7 ± 108.1, 367.9 ± 83.9, at 10 and 14 weeks,
respectively, all units are μg mg–1) and was rescued by
over-expressionofVEGF-A165bunder anephrinpromoter
(VEGF-A-KO × Neph-VEGF-A165b; 51.1 ± 10.6,
114.2 ± 13.3, at 10 and 14 weeks, respectively, all
units are μg mg–1) (P < 0.05; two-way ANOVA)
(Fig. 2A). No significant increase in plasma creatinine
was observed in VEGF-A-KO mice (Fig. 2B). However,
glomerular water permeability was increased in a
manner similar to albuminuria in VEGF-A-KO mice,
which was rescued by constitutive expression of
VEGF-A165b at 10 weeks post-induction (Fig. 2C)
but not at 14 weeks (Fig. 2D) (WT; 0.36 ± 0.035,
0.4 ± 0.055. VEGF-A-KO; 0.54 ± 0.049, 0.78 ± 0.053.
VEGF-A-KO × Neph-VEGF165b; 0.23 ± 0.028,
0.6 ± 0.079, at 10 and 14 weeks, respectively, all units
are mmHg−1 min−1) (P < 0.05; one-way ANOVA).
Structural studies
KD of podocyte VEGF-A expression in VEGF-A-KOmice
did not induce any glomerulosclerosis after 14 weeks, as
assessed by the GSI scoring of PAS stained kidney cortex
(Fig. 3A and B). Furthermore, VEGF-A-KO mice did not
develop any glomerular fibrosis (Fig. 3A and C), as shown
by Masson’s trichrome staining of the kidney cortex. The
over-expression of podocyte VEGF-A165b also had no
effect on glomerulosclerosis and fibrosis in these mice.
Therefore, the inducible KD of podocyte VEGF-A did not
result in a model of glomerulosclerosis in these mice.
Transmission electron microscopy analysis on samples
collected after 10 and 14 weeks doxycycline induction
revealed that the average podocyte foot process width
did not change significantly across experimental groups
(Fig. 4B). However, VEGF-A-KO mice did develop an
increased GBM width at both 10 and 14 weeks. Values
returned to those observed in WT littermates when
VEGF-A165b was over-expressed in the kidneys (WT;
174.06 ± 1.42 nm, VEGF-A-KO; 205.32 ± 4.02 nm,
VEGF-A-KO × Neph-VEGF165b; 167.8 ± 2.92 nm)
(Fig. 4C). The number of endothelial fenestrations was
significantly decreased in both the VEGF-A-KO and
VEGF-A-KO × Neph-VEGF165b glomeruli (Fig. 4D).
The SPS coverage was significantly decreased in
VEGF-A-KO glomeruli, and was rescued in VEGF-A165b
over-expressors, only at 10 weeks (Fig. 4E). VEGF-A-KO
mice had an increased average slit width between the
podocyte foot processes, which was fully rescued in
VEGF-A-KO × Neph-VEGF-A165b mice at both 10 and
14 weeks (Fig. 4F).
Decreased PECAM-1 expression and glomerular
capillary circumference by VEGF-A depletion is
rescued by VEGF-A165b over-expression
To further investigate potential molecular mechanisms by
which VEGF-A165b is able to rescue the above-described
phenotype,we carriedout immunofluorescence onkidney
cortex sections for various podocyte and endothelial
cell markers, and investigated their expression using
western blotting. Using immunofluorescence, podocin
and PECAM-1 expression were both decreased in
VEGF-A-KOmice at 14 weeks post-induction. PECAM-1
(althoughnotpodocin) expressionwaspartially rescued in
VEGF-A-KO × Neph-VEGF-A165b mice (Fig. 5A and B).
However, western blotting only detected a reduction in the
expressionof PECAM-1 in theVEGF-A-KOkidney cortex,
which was rescued in VEGF-A-KO × Neph-VEGF-A165b
mice (Fig. 5C andD).Nephrin expressionwas not changed
across the littermate groups. Interestingly, capillary
circumference and capillary density were also decreased
in VEGF-A-KO glomeruli, and this was rescued by
over-expression of VEGF-A165b in the podocytes (Fig. 5E
and F). Taken together, these results suggest that the
protective effect of VEGF-A165b in vivo is mediated via
actions on the endothelial cell compartment.
VEGF-A165b increases expression of VEGFR2 in
glomerular endothelial cells in VEGF-A-KO ×
Neph-VEGF-A165b mice
VEGF-A165b is reported to signal through VEGFR2
activation in human umbilical vein endothelial cells
(Cebe Suarez et al. 2006). We recently showed that,
in Neph-VEGF-A165b mice, podocytic VEGF-A165b
induces both increased expression and phosphorylation
of VEGFR2 in glomerular endothelial cells in vivo
(Oltean et al. 2015). We therefore investigated whether
a VEGF-A165b -mediated rescue of VEGFR2 expression
in VEGF-A-KO mice could account for the phenotypic
rescue observed.
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Immunofluorescence staining and western blotting
demonstrated that there was an up-regulation of the
receptor expression in VEGF-A-KO×Neph-VEGF-A165b
glomeruli compared to VEGF-A-KO (Fig. 6A–D).
The increase in VEGFR2 demonstrates the protective
effects of VEGF-A165b on the glomerular endothelium.
Furthermore, when investigating the effects of chronic
VEGF-A-KO and over-expression of VEGF-A165b on
the VEGF-A signalling pathway, we found that a KO of
VEGF-A resulted in an up-regulation in the glomerular
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Figure 2. VEGF-A-KO mice develop albuminuria and have increased glomerular water permeability,
which is rescued in VEGF-A-KO × Neph-VEGF-A165b mice
A, uACR was determined from urine samples at 0, 4, 10 and 14 weeks after induction with doxycycline
(n = 4–12 mice per time point). The uACR significantly increased in VEGF-A-KO mice at weeks 10 and 14
compared to WT littermate controls. This was fully rescued in VEGF-A-KO × Neph-VEGF-A165b mice (∗P < 0.05;
two-way ANOVA, correction for comparison between pairs). B, VEGF-A-KO mice did not develop increased plasma
creatinine at the 14 week time point. VEGF-A-KO mice had a significantly increased glomerular water permeability
(LpA/Vi) at both 10 (C) and 14 (D) weeks after induction with doxycycline. This was fully rescued in the VEGF-A-KO
× Neph-VEGF-A165b mice at the 10 week time point; however, there was no significant rescue by VEGF-A165b
at 14 weeks (n = 4–9 mice, 15–30 glomeruli; ∗P < 0.05; one-way ANOVA, Bonferroni correction for comparison
between pairs). [Colour figure can be viewed at wileyonlinelibrary.com]
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
8 M. Stevens and others J Physiol 000.00
expression of Akt and ERK1/2, both of which were also
observed in VEGF-A-KO × Neph-VEGF-A165b glomeruli
(Fig. 6E and G). However, chronic VEGF-A-KO resulted
in decreased activity of these kinases, as indicated by a
reduction in the phosphorylation of Akt at Serine 453,
as well as no change in the phosphorylation of ERK1/2.
This was altered by the over-expression of VEGF-A165b,
resulting in an increase in the phosphorylation of the
cyto-protective Akt, and a decrease in the phosphorylation
of ERK1/2 (Fig. 6F).
To confirm that VEGF-A165b could act through
VEGFR2 in ciGEnCs, as well as to understand the
differences between the two splice isoforms, cells were
treated with VEGF-A165, VEGF-A165b, or both. All
treatments increased the expression of VEGFR2 at 48
h (Fig. 7A, B), as observed in vivo. Phosphorylation of
VEGFR2 was robustly increased by VEGF-A165 and a
combination treatment of VEGF-A165 and VEGF-A165b
at 5 min, which was diminished 1 h later. However,
VEGF-A165b treatment alone did not induce VEGFR2
phosphorylation at either time point (Fig. 7C and
D). When looking downstream of VEGFR2 activation,
both isoforms of VEGF-A result in an increase in the
phosphorylationofp42MAPK(ERK1)andAkt after 5min
of treatment in ciGEnCs (Fig. 7E and F).
VEGF-A165b differentially regulates a set of genes
in GEnCs compared to VEGF-A165
To further understand the molecular pathways by which
VEGF-A165b mediates its effects in the glomerulus
compared to VEGF-A165, we used a custom-designed
quantitative RT-PCR array specific for the VEGF-A
signalling axis (TaqMan Fast Human VEGF-A PCR
array; Applied Biosciences; 44 candidate genes plus four
control genes). Six genes were differentially expressed
during VEGF-A165b treatment compared to VEGF-A165
(Fig. 8A and B). ACTG1 and SHC1 are involved in end-
othelial cell migration, mitogenesis and apoptosis, and
were further validated by quantitative RT-PCR (Fig. 8C).
Their expression is increased by VEGF-A165 but decreased
by VEGF-A165b, providing a possible explanation for
the protective effects of VEGF-A165b on glomerular
vasculature. To confirm these findings in vivo, we first
analysed the protein expression of the two genes in kidney
cortex extracts from Neph-VEGF-A165b over-expressors
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Figure 3. VEGF-A-KO mice do not develop glomerulosclerosis or fibrosis
A, periodic acid-Schiff (PAS) (Aa–Ac) and Masson’s trichrome blue (Ad–Af) staining was performed to assess
glomerulosclerosis and fibrosis. B, VEGF-A-KO mice did not develop any significant glomerulosclerosis (GSI) after
14 weeks (n = 3 mice, 25–30 glomeruli per mouse; P = not significant; one-way ANOVA, Bonferroni correction for
comparison between pairs). C, VEGF-A-KOmice also did not develop glomerular fibrosis after 14weeks (n= 3mice,
21–28 glomeruli per mouse; P = not significant; one-way ANOVA, Bonferroni correction for comparison between
pairs). No changes were observed in VEGF-A-KO × Neph-VEGF-A165b kidneys. [Colour figure can be viewed at
wileyonlinelibrary.com]
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Figure 4. VEGF-A-KO mice develop several ultrastructural abnormalities, some of which are rescued in
VEGF-A-KO × Neph-VEGF-A165b mice
A, VEGF-A-KOmice did develop ultrastructural abnormalities (10 weeks;Aa–Ac, 14 weeks;Ad–Ac). Although there
was no difference in foot process width at either time point (P > 0.05), (B) VEGF-A-KO mice develop thickening
of the GBM after both 10 and 14 weeks of doxycycline (∗P < 0.05) compared to the control, which was fully
rescued in the VEGF-A-KO × Neph-VEGF-A165b mouse (†P < 0.05) (C). VEGF-A-KO mice also had a significant
reduction in endothelial fenestrae number per µm length of GBM (D), although there was no significant rescue in
the VEGF-A-KO × Neph-VEGF-A165b mice at either time point (∗P < 0.05). E, VEGF-A-KO mice had a reduction in
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SPS coverage of the GBM compared to WT controls (∗P < 0.05), which was significantly rescued in the VEGF-A-KO
× Neph-VEGF-A165b mice at 10 weeks but not 14 weeks (†P < 0.05). F, VEGF-A-KO mice had increased slit width
between the podocyte foot processes (∗P < 0.05), which was fully rescued in the VEGF-A-KO × Neph-VEGF-A165b
mice (†P < 0.05) (n = 3 mice; three gloms per mouse; one-way ANOVA, Bonferroni correction for comparison
between pairs).
compared to WT littermates. Although ACTG1 is not
changed (it is possibly easier to see a difference in
glomerular extracts), there is a decrease in SHC1 in
Neph-VEGF-A165b over-expressors (Fig. 8D and E).
Discussion
Despite progress made in recent years, CKD remains a
major health challenge worldwide not only because of the
immense burden of end-stage renal disease and chronic
dialysis, but also as a result of systemic cardiovascular
complications and associated morbidities (Matsushita
et al. 2010). Therefore, it is critical to further our
understanding of the molecular mechanisms disrupted
during CKD progression, as well as to find ways of
manipulating them for therapeutic benefit. Without
doubt, CKD is multifactorial and extremely complex in
its pathogenesis; we can certainly progress our under-
standing by studying individual genes that have been
shown to be tightly associated with CKD progression.
One such gene is VEGF-A, whose involvement in different
renal pathologies has been studied for over 20 years, and
it was recently shown to correlate with the estimated
GFR in patients with CKD (Martini et al. 2014). This is
the first study to assess the effects of podocyte-specific
VEGF-A165b over-expression in a model of podocyte
depletion of other isoforms of VEGF-A. To study the
specific effect of only VEGF-A and its splice isoforms on
kidney function, we used an inducible, podocyte-specific
VEGF-A-KO mouse where the VEGF-A165b isoform
could be over-expressed in a constitutive manner. The
advantage of using this model compared to other widely
used chronic kidney disease models, such as the 5/6
nephrectomy and unilateral ureteric obstruction models,
is that we can look specifically at the effect of VEGF-A
expression and splicing on kidney function.
In our mice, VEGF-A levels were progressively depleted
from the kidney to40% at 14 weeks post-induction with
doxycycline. This was the case in both the VEGF-A-KO
and the VEGF-A-KO × Neph-VEGF-A165b model with
respect to VEGF-A164, with the exception that the
VEGF-A-KO×Neph-VEGF-A165bmouse over-expressed
specifically the VEGF-A165b isoform in the podocytes.
This over-expression did not have an effect on the
depletion of total mouse VEGF-A. The VEGF-A-KO
did not result in a dramatic deterioration in kidney
function, asdescribedpreviously in some studies (Eremina
& Quaggin, 2004; Eremina et al. 2008). This is not
unexpected because we only target one gene in what is a
very complex andmultifactorial systemof normal,mature
glomerular function. We instead develop a model of
microalbuminuria and increased glomerular permeability
as a result of ultrastructural glomerular changes in
response to a progressive KD of podocyte VEGF-A
expression. Inourmice,KOwas inducedover a10–14week
period, once the mice had reached maturity (> 8 weeks
of age). In previous studies, KO was induced during
pre- or postnatal development (3–3.5 weeks) (Eremina
& Quaggin, 2004; Sivaskandarajah et al. 2012) when
the glomerulus is still forming, which results in a more
severe phenotype as a result of the important role that
VEGF-A plays in glomerular development (Eremina &
Quaggin, 2004). Interestingly, small interfering RNA KD
also caused a more severe phenotype (Veron et al. 2012),
even when induced in adult mice. Differences might
also be related to strain/genetic background, animal
facility or the presence of associated confounding factors.
Our mice were generated on a C57BL/6 background
because many genetically modified mice are a result
of the advantages of this strain (Seong et al. 2004),
which is now widely accepted to be resistant to severe
albuminuria and glomerulosclerosis (Zheng et al. 1998).
In our mice, we observed an increase in proteinuria at
10 and 14 weeks post-induction with doxycycline; thus,
we obtained a model that mimics the correlation between
decreased levels of VEGF-A and CKD progression seen
in humans with respect to proteinuria (Martini et al.
2014). Over-expression of VEGF-A165b is able to rescue
proteinuria, as well as glomerular water permeability, a
sensitive measure of kidney function (Salmon et al. 2006).
At 14 weeks, there is no full rescue of the glomerular
water permeability by over-expression of VEGF-A165b,
as seen at 10 weeks, which is probably a result of
the further depletion of podocyte VEGF-A expression
between these time points (40–60% depletion) giving rise
to a more severe phenotype (Figs 1 and 2). We would
have expected the rescue of the uACR by VEGF-A165b
at 14 weeks to be reflected in the glomerular water
permeability measurements at the same time point, in
the same mice. However, as previous studies using this
technique have demonstrated (Oltean et al. 2012; Oltean
et al. 2015), this is not always the case. The glomerular
water permeability assay is a more sensitive technique and
thus is representative of individual glomeruli, whereas the
uACR measurements are reflective of the whole kidney
function and can be less sensitive. Furthermore, the assays
measure two different factors (i.e. water and albumin)n
under different conditions; therefore, small differences in
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Figure 5. VEGF-A-KO mice have an altered endothelial phenotype, which is rescued in VEGF-A-KO ×
Neph-VEGF165b mice
A, sections from all three mice genotypes were stained for podocyte markers (podocin and nephrin) and endothelial
marker (PECAM-1). VEGF-A-KO mice had reduced glomerular podocin and PECAM-1 staining, normalized to
glomerular area, compared toWT controls, 14weeks after inductionwith doxycycline. This was significantly rescued
in the VEGF-A-KO × Neph-VEGF-A165b glomeruli. However, nephrin staining remained unchanged between
groups (n= 3mice, 36–48 glomeruli per mouse; ∗P< 0.05; one-way ANOVA, Bonferroni correction for comparison
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between pairs). Quantification of the staining normalized to glomerular area is represented graphically in (B). C and
D, western blotting showed only a change in the protein expression of PECAM-1 occurred (Cb), with a reduction
in expression found in VEGF-A-KO mice, which is rescued by podocyte over-expression of VEGF-A165b. Expression
of the podocyte proteins nephrin and podocin remain unchanged (Ca), (n = 4 mice; ∗P < 0.05; one-way ANOVA,
Bonferroni correction for comparison between pairs). E, the capillary loop circumferencewas reduced in VEGF-A-KO
glomeruli compared to WT controls, which was significantly rescued in the VEGF-A-KO × Neph-VEGF-A165b
glomeruli (n = 3 mice, 36–50 glomeruli per mouse, two or three loops per glomerulus; ∗P < 0.05; one-way
ANOVA, Bonferroni correction for comparison between pairs). F, the capillary density normalized to glomerular area
was reduced in VEGF-A-KO mice relative to WT controls, which was rescued in VEGF-A-KO × Neph-VEGF-A165b
mice (n = 3 mice, 36–52 glomerular sections per mouse; ∗P < 0.05; one-way ANOVA, Bonferroni correction for
comparison between pairs). [Colour figure can be viewed at wileyonlinelibrary.com]
the measurements are expected and this explains why
we carry out both techniques on all mice. Because of
the increased depletion of podocyte VEGF-A observed
at 14 weeks compared to 10 weeks, we decided to focus
much of our analysis on this later time point.
No major structural abnormalities such as
glomerulosclerosis and fibrosis were found in this
model (Fig. 3), which explains why we only observe a
mild phenotype with progressive depletion of podocyte
VEGF-A. Ultrastructural (electron microscopy) studies
found moderate alterations in glomerular structure
(Fig. 4), including a modest increase in GBM thickness,
as observed in another published model of podocyte
VEGF-A-KO (Eremina et al. 2008). Alterations to
the podocytes included an increase in the slit width,
indicating the beginnings of foot process effacement.
This was rescued in VEGF-A-KO × NephVEGF-A165b
mice. Nephrin expression is not changed across
experimental groups (Fig. 5), suggesting that the slit
width modifications may be a result of the rearrangement
of nephrin (or other slit proteins) bonds. Interestingly, we
also observed a decrease in SPS coverage similar to that
observed whenVEGF-A164 is over-expressed in the kidney
in a previously published transgenic model (Oltean et al.
2012). As observed in the VEGF-A164 over-expression
model, SPS coverage is rescued by VEGF-A165b in the
model used in the present study, suggesting that the
differences in the ways the two splice isoforms interact
with their receptors and the consequent functions depend
on their absolute abundance. Therefore, it appears that
one of the mechanisms by which VEGF-A165b is acting
in the kidney to reduce glomerular water permeability
under pathological conditions is by maintenance of SPS
coverage. Ultrastructural alterations to the glomerular
endothelial cells, where VEGF-A signalling occurs,
included a reduction in fenestrae number in VEGF-A-KO
mice. VEGF-A is critical for production and maintenance
of endothelial fenestrae because a reduction in VEGF-A
signalling has previously shown a loss of the normal
fenestrated phenotype (Oltean et al. 2015) and treatment
of ciGEnCs with VEGF-A has been shown to induce
fenestrations in vitro (Satchell et al. 2006). The reduction
in endothelial fenestration number remained decreased
in VEGF-A-KO × NephVEGF-A165b mice, which is
probably a result of the previously described effect that
VEGF-A165b has on endothelial fenestrae closure (Qiu
et al. 2010).
Although we did not obtain a full KO of VEGF-A
from the podocytes, the evidence presented suggests that
over-expression of VEGF-A165b is not only beneficial to
the kidney, but also appears to be sufficient to maintain
glomerular function in this model. How is the action
of VEGF-A165b mediated in the kidney and how is it
different to that of VEGF-A165? Staining with podocyte
and endothelial specific markers indicated that the rescue
effect of VEGF-A165b is mediated through restoring end-
othelial cell expression, as demonstrated by an increase
in PECAM-1 and VEGFR2, and glomerular capillary
circumference (Fig. 5). Although we did not observe any
changes in the expression of VEGFR2 using immuno-
fluorescence, we consider this to be a result of the
technique itself; assessment of protein expression with
immunofluorescence can give variable results depending
on the area of the glomerulus being sectioned. Western
blotting is a more accepted method for the quantification
of protein expression. We also cannot rule out tubular
contamination in the sieved glomeruli protein extract used
in thewesternblotting,which could indicate that podocyte
depletion of VEGF-A could induce tubular changes
in these mice. Future experiments could investigate
this. VEGF-A165b increases the glomerular expression
of VEGFR2 in vivo (Fig. 6), as previously described by
Oltean et al. (2015), and appears to be acting through
VEGFR2 in the glomerulus, as demonstrated by the
decrease in glomerular water permeability in the presence
of tyrosine kinase inhibitors, although other receptors
cannot be fully ruled out. Downstream of VEGFR2,
a KO of VEGF-A and over-expression of VEGF-A165b
both increased the expression of the kinases Akt and
ERK1/2. However, the kinase activity of Akt is reduced
in VEGF-A-KO glomeruli, probably as a result of a lack
of VEGFR signalling. This is reversed by VEGF-A165b
over-expression, suggesting that VEGF-A165b is signalling
via a VEGFR that has cyto-protective effects, such as
reduced endothelial cell apoptosis, restoring normal
glomerular function. Although chronic exposure to
VEGF-A165b increases the phosphorylation of Akt, it had
the opposite effect on the phosphorylation of another
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Figure 6. VEGF-A165b may act through VEGFR2 in glomerular endothelial cells in vivo
Glomerular VEGFR2 staining (green) (A), normalized to glomerular area, was increased in VEGF-A-KO ×
Neph-VEGF-A165b (c) glomeruli compared to WT (a) and VEGF-A-KO (b) controls (B) (n = 3 mice, 14–17
glomeruli, ∗P < 0.05; one-way ANOVA, Bonferroni correction for comparison between pairs). C, protein
from sieved glomeruli showed VEGFR2 expression to be reduced in VEGF-A-KO mice compared to WT
controls. VEGF-A-KO × Neph-VEGF-A165b mice have rescued VEGFR2 glomerular protein expression, with the
analysis shown in (D) (n = 5, ∗P  0.05; one-way ANOVA, Bonferroni correction for comparison between
pairs). E, VEGF-A-KO induces a reduction in the phosphorylation of Akt (Ser 453), which is reversed in the
VEGF-A-KO × Neph-VEGF-A165b glomeruli (F). VEGF-A-KO induces no change in the phosphorylation of ERK1/2;
however, VEGF-A-KO × Neph-VEGF-A165b glomeruli have a reduction in ERK1/2 phosphorylation relative to
WT glomeruli (E and F). G, glomerular Akt and ERK1/2 expression is increased in both VEGF-A-KO and
VEGF-A-KO × Neph-VEGF-A165b mice relative to WT controls (n = 4, ∗P < 0.05 WT vs. VEGF-A-KO, ✧P < 0.05
VEGF-A-KO vs. VEGF-A-KO × Neph-VEGF-A165b; one-way ANOVA, Bonferroni correction for comparison between
pairs). [Colour figure can be viewed at wileyonlinelibrary.com]
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kinase; ERK1. Activation of ERK1 was reduced, which is
reflective of previous studies reporting that VEGF-A165b
rapidly inactivates VEGFR2 phosphorylation, therefore
resulting in a weak, transient phosphorylation of
downstream targets such as ERK1/2 (Kawamura et al.
2008). Interestingly, the same study reported a similar
effect on the phosphorylation of Akt in response to
VEGF-A165b, thereby providing further evidence for the
possibility of VEGF-A165b acting through other receptors
in the glomerulus.
This is the first study to assess the effects of VEGF-A165b
treatment of ciGEnCs in culture, providing further
mechanistic evidence of the role played by VEGF-A165b
in the glomerulus. The increase in expression of VEGFR2
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Figure 7. VEGF-A165 and VEGF-A165b increase the expression but have different effects on
phosphorylation of VEGFR2 in ciGEnCs
Differentiated ciGEnCs were treated with 1 nM VEGF-A165, VEGF-A165b, or a combination of both for 48 h (A)
and expression of VEGFR2 measured by immunoblotting. B, VEGFR2 was increased in all treatments compared to
the untreated control (n = 3, ∗P < 0.05, one-way ANOVA, Bonferroni correction for comparison between pairs).
No change in expression of VEGFR2 was observed at treatment times shorter than 48 h. Ca and Cb, treatment
with VEGF-A165, and a combination of VEGF-A165 and VEGF-A165b induced phosphorylation of VEGFR2 after
5 min, which was diminished after 1 h. However, no phosphorylation of the receptor was seen with treatment
of VEGF-A165b alone. D, phosphorylation of VEGFR2 was normalized to VEGFR2 expression, and then to control
(n = 3, ∗P < 0.05, one-way ANOVA, Bonferroni correction for comparison between pairs). E, both VEGF-A
isoforms resulted in an increase in the phosphorylation of ERK1 and Akt in GEnCs after 5 min of treatment. F,
phosphorylation of ERK1 and Akt was normalized to total ERK1 and Akt expression, and then to control (n = 4 or
5, ∗P < 0.05, one-way ANOVA, Bonferroni correction for comparison between pairs).
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Figure 8. VEGF-A165b differentially regulates the expression of several candidate genes in the human
VEGF-A signalling pathway in ciGEnCs
A, a TaqMan Fast PCR Array for the the human VEGF-A pathway highlighted six candidate genes (B) that were
significantly down-regulated by 1 h of treatment with VEGF-A165b compared to VEGF-A165 in ciGEnCs; ACTB,
ACTG1, HRAS, HSP90AA1, NRAS and SHC1 (n = 4, ∗P < 0.05, Student’s t test for comparison between groups).
C, quantitative RT-PCR validation of the six candidate genes using gene specific primers confirmed that two of the
genes were significantly down-regulated by 1 h of treatment with VEGF-A165b compared to VEGF-A165: ACTG1
and SHC1 (n = 4, ∗P < 0.05, Student’s t test for comparison between groups). D, up-regulation of SHC1 (but not
ACTG1) protein expression in the kidney cortex was observed in Neph-VEGF-A165b over-expressing mice. Protein
expression shown relative to WT control expression (E) (n = 3, ∗P < 0.05, Student’s t test for comparison between
groups). [Colour figure can be viewed at wileyonlinelibrary.com]
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can be reproduced in vitro by treating ciGEnCs with
VEGF-A165b (Fig. 7). Although VEGF-A165b did not
induce phosphorylation of VEGFR2, it did result in
the initial phosphorylation of ERK1 and Akt, as pre-
viously reported in humanmicrovascular endothelial cells
(Kawamura et al. 2008), both of which are pro-survival
factors in endothelial cells. Once again, this could indicate
that, although inhibitory to VEGFR2, VEGF-A165b may
be signalling via other receptors in GEnCs, of which are
yet to be determined.
A VEGF-A pathway PCR array revealed decreased
expression of ACTG1 and SHC1 mRNA when
ciGEnCs were stimulated with VEGF-A165b compared
to VEGF-A165 (Fig. 8). When looking at the expression
of these two proteins in the renal cortex of mice
that over-express VEGF-A165b in the podocytes, we
see a down-regulation of SHC1, although not ACTG1
expression, mimicking that seed in culture with regard
to SHC1. These genes are involved in migration and
proliferation of endothelial cells in response to VEGF-A
signalling (Cross et al. 2003; Oshikawa et al. 2012) and
the down-regulation of SHC1 provides some insight
into the mechanism of action of VEGF-A165b under
normal physiological conditions. Interestingly, a KO of
SHC1 has been shown to be protective in a model
of albuminuria (Menini et al. 2006). However, when
there is a KD of VEGF-A in the glomeruli, VEGF-A165b
over-expression results in the opposite effect on ACTG1
and SHC1, no longer down-regulating the expression of
the two proteins. Therefore, it is apparent that a change
in the balance of the two isoform families can alter
the downstream signalling pathways that are activated.
This also gives increasing strength to the hypothesis that
VEGF-A165b is acting on other receptors, such as VEGF
receptor 1 and platelet derived growth factor receptor
(Cumpanas et al. 2016), or is resulting in a transient weak
phosphorylation of VEGFR2, as described previously,
which we were unable to detect in our GEnCs (Kawamura
et al. 2008). Further investigations are required to clarify
the complex pathways involved in the VEGF-A165b
mechanistic action. However, it is evident that the ratio
of VEGF-Axxx/VEGF-Axxxb expression determines the
downstream pathways activated/inhibited.
In conclusion, the present study demonstrates that the
VEGF-A165b splice isoform is sufficient to support kidney
function in a podocyte specific VEGF-A-KO model of
microalbuminuria, andmay explain why treatments using
bevacizumab, an antibody against all forms of VEGF, are
deleterious to the kidney (Eremina et al. 2008). In a recent
study, we reported that patients with early stage diabetic
nephropathy appear to up-regulate VEGF-A165b isoform
expression in the kidney as a compensatory mechanism;
however, this is lost with disease progression (Oltean et al.
2015). Together with the findings of the present study, we
have gained further evidence for the importance of the
VEGF-A splicing ratio in kidney function. The present
study has enabled us to determine the protective effects of
VEGF-A165b in a model when all other VEGF-A isoforms
are depleted, and novel mechanistic evidence is provided
regarding the importance of the VEGF-A splicing ratio
in kidney function, specifically in glomerular endothelial
cells. Therefore, there is a compelling case for investigating
the therapeutic avenues that aim to switch splicing towards
VEGF-A165b in the kidney with the potential to slow
the progression of CKD via the protection of kidney
function.
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Translational perspectives
Chronic kidney disease (CKD) is a major health problem that affects15% of people in the Western
world. A large proportion of these patients progress to end-stage renal failure and dialysis, resulting
in increasing costs in healthcare. It is therefore very important to further understand CKD disease
mechanisms and to develop novel therapeutic approaches. Vascular endothelial growth factor A
(VEGF-A) is essential in maintaining kidney homeostasis, with both increases and decreases in
expression being associated with kidney malfunction. There is a strong association of decreased
VEGF-A levels with CKD. The splice isoform VEGF-A165b has been previously shown to be
renoprotective. In the present study, we demonstrate, in a mouse model of microalbuminuria with
progressive depletionof all VEGF-A isoforms from the kidney, that over-expressionof theVEGF-A165b
isoform alone rescues the phenotype. This suggests that modulation of VEGF-A splicing may be a
viable therapeutic avenue for CKD.
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